Adiponectin is a fat-tissue hormone with a counterintuitive property: its levels fall as body fat increases, precisely when its metabolic protection is most needed. Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease¹¹ Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. The metabolic effects of adiponectin depend entirely on two transmembrane receptors: ADIPOR1, which is dominant in skeletal muscle, and ADIPOR2, which is dominant in the liver. rs1058322 is an intronic variant in ADIPOR2 — it does not change the receptor's amino acid sequence, but carriers of the T allele show measurably lower ADIPOR2 mRNA expression in circulating immune cells, suggesting the variant influences gene expression through altered splicing or regulatory context.

The Mechanism

When adiponectin binds ADIPOR2 in the liver, two downstream pathways activate: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master metabolic sensor that shifts cells toward catabolism, increasing fatty acid oxidation and glucose uptake while suppressing hepatic fat synthesis and gluconeogenesis and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that transcribes genes for hepatic fatty acid oxidation and lipid export; ADIPOR2 is its primary activator in liver. Together, these reduce hepatic fat accumulation, improve insulin sensitivity, lower LDL, and suppress inflammatory lipid species. The T allele at rs1058322 appears to reduce ADIPOR2 expression, leaving fewer functional receptor molecules at the hepatocyte membrane — the adiponectin signal arrives but finds fewer docking stations, blunting both AMPK and PPARα activation. The net result is a liver that is measurably less responsive to adiponectin's metabolic protection.

The Evidence

The primary evidence comes from the Finnish Diabetes Prevention Study (DPS)⁴⁴ Finnish Diabetes Prevention Study (DPS)
A randomized lifestyle intervention trial in Finland enrolling individuals with impaired glucose tolerance (IGT); 484 participants were genotyped for ADIPOR2 variants and followed for a median of 10.2 years for cardiovascular events. The rs1058322 T allele was dose-dependently associated with higher CVD risk: the additive model showed HR 1.601 (95% CI 1.021–2.509, p = 0.040) and the dominant model HR 1.711 (95% CI 1.114–2.627, p = 0.014). When rs1058322 was tested alongside three other ADIPOR2 variants in a joint multi-SNP model, it remained a significant independent predictor (p = 0.020), indicating unique risk information not redundant with other ADIPOR2 loci (r² = 0.094 with rs11061937).

The expression data that mechanistically links the variant to risk comes from the Genobin sub-study within the DPS analysis (n = 56)⁵⁵ Genobin sub-study within the DPS analysis (n = 56)
A Finnish metabolic cohort used to validate expression phenotypes discovered in the DPS genetic analysis; Siitonen et al. Cardiovasc Diabetol, 2011. Carriers of the T allele showed significantly lower ADIPOR2 mRNA levels in peripheral blood mononuclear cells compared with CC homozygotes (p = 0.029), providing a biological mechanism: T allele → reduced receptor expression → blunted adiponectin signaling → elevated cardiometabolic risk.

The broader biology is supported by receptor-disruption experiments: AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism⁶⁶ AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism
Bjursell M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007. Synthetic ADIPOR agonists that activate both receptors reduce insulin resistance and extend lifespan in obese diabetic mice⁷⁷ reduce insulin resistance and extend lifespan in obese diabetic mice
Okada-Iwabu et al. AdipoRon improves obesity-related metabolic disease. Nature, 2013, validating the pathway as therapeutically relevant and confirming that augmenting receptor signaling can meaningfully offset metabolic risk.

Practical Actions

The actionable targets for this variant are strategies that raise circulating adiponectin concentration — increasing the ligand supply to partially compensate for reduced receptor density — and that support hepatic fatty acid oxidation and AMPK activation independently. Omega-3 fatty acids (EPA and DHA) raise serum adiponectin in intervention studies and are the most directly relevant dietary lever. Replacing saturated fat with polyunsaturated sources raises adiponectin by 10–15% in dietary intervention trials. Given the CVD signal from the Finnish DPS, cardiometabolic monitoring is appropriate for T allele carriers, particularly those with additional risk factors such as impaired fasting glucose, elevated triglycerides, or a family history of cardiovascular disease.

Interactions

rs1058322 was co-analyzed with rs11061937, rs10848554, and rs16928751 in the Finnish DPS; all four SNPs showed nominal CVD associations and rs1058322 maintained independent significance alongside rs11061937 in the multi-SNP model. These variants tag distinct positions across the ADIPOR2 locus and may collectively describe a haplotype with compounded effects on receptor expression or function. Individuals carrying T alleles at rs1058322 alongside risk alleles at rs11061937 may have a more substantially reduced hepatic adiponectin response than either variant alone predicts. The interaction warrants a compound action (see harvesting notes below).

Aromatase — encoded by CYP19A1 on chromosome 15 — is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone) in peripheral tissues. Unlike the ovaries and testes, which produce estrogen in bulk, bone, fat, liver, brain, and breast tissue rely on local aromatase activity to maintain estrogen sufficiency around individual cells. rs1062033 sits approximately 12 kilobases upstream of the CYP19A1 translation start site in a regulatory region that controls which tissues express aromatase and in what amounts. This variant alters the binding of CEBPβ¹¹ CEBPβ
CCAAT/enhancer-binding protein beta, a transcription factor that regulates tissue-specific gene expression to the promoter, producing allele-specific differences in aromatase expression that downstream affect local estrogen concentrations — particularly in bone.

The Mechanism

The rs1062033 C>G change lies in an intronic regulatory region of CYP19A1 that acts as a tissue-specific promoter element. Electrophoretic mobility shift assays demonstrated that the C and G alleles bind the CEBPβ transcription factor with different affinities, and transient transfection experiments in osteoblastic cells showed allele-specific differences in luciferase reporter activity when a CEBPβ expression vector was co-introduced. Critically, differential allelic expression was confirmed directly in human bone tissue samples — not just in cell culture — making this one of the few CYP19A1 regulatory variants with direct in-tissue functional evidence rather than predicted regulatory effects alone.

The practical consequence flows through estrogen's effects on bone remodeling: estradiol suppresses osteoclast activity (bone breakdown) and supports osteoblast survival (bone formation). Women with alleles that sustain higher local aromatase activity in bone cells maintain greater estrogen-driven bone protection even as circulating ovarian estrogen declines after menopause. The interaction with vitamin D and calcium is indirect: estrogen upregulates calcium absorption in the gut (via calcium-binding protein calbindin-D9k²² calcium-binding protein calbindin-D9k
CALB1) and reduces urinary calcium loss — so allele-driven differences in aromatase activity propagate into effective calcium and vitamin D utilization in bone.

The Evidence

The foundational study by Riancho et al. 2009³³ Riancho et al. 2009
J Bone Miner Res — 1,163 postmenopausal women; rs1062033 as a true regulatory polymorphism with CEBPβ-binding evidence and allele-specific expression in human bone showed that opposing homozygotes (CC vs. GG) differed by 4.2% in whole-cohort BMD, a difference that expanded to 7.3% in women older than 67 — the age group with the greatest cumulative loss of ovarian estrogen support. This dose-response pattern across age is consistent with a lifetime accumulation of allele-driven differences in local bone estrogen signaling.

A Chinese Han case-control study Chen et al. 2024⁴⁴ Chen et al. 2024
Bladder cancer; 217 cases, 550 controls; OR=0.36 for G vs. C, FDR-p<0.001; rs1062033 correlated with CYP19A1 expression in whole blood independently confirmed that rs1062033 modifies CYP19A1 expression levels in blood, and found the G allele strongly protective against bladder cancer — a tissue where estrogen signaling is known to influence carcinogenesis risk.

The variant also modifies hormone circulating levels in response to environmental exposures. Kopp et al. 2016⁵⁵ Kopp et al. 2016
BMC Cancer — 687 cases/controls; rs1062033 associated with estrone sulphate levels (p=0.007) and interacted with alcohol to influence circulating hormone concentrations (p-interaction=0.03) demonstrated that the genotype influences baseline circulating estrone sulphate independently of hormone replacement therapy, and that the gene-environment interaction with alcohol is allele-specific.

Practical Actions

The primary clinical implication of this variant is in bone health for postmenopausal women. Carriers of two C alleles have lower aromatase-driven local estrogen in bone tissue, particularly relevant after menopause when peripheral aromatization becomes the dominant estrogen source. For these individuals, optimizing the cofactors that amplify bone-protective signaling — adequate vitamin D for calcium absorption, calcium intake distributed across meals for absorption efficiency, and weight-bearing activity to provide mechanical stimulus — becomes more important than for GG carriers, who retain higher local aromatase expression. Bone density monitoring starting from perimenopause is advisable to detect loss early when intervention is most effective.

Men also express aromatase in bone tissue, and testosterone therapy outcomes differ by rs1062033 genotype — indicating the variant's regulatory role in bone is not sex-exclusive, though the effect is smaller and evidence thinner in men.

Interactions

rs1062033 interacts epistatically with the IL-10 promoter variant rs1800896 in Alzheimer's disease risk — but only in women, with a synergy factor of 1.94 in the Epistasis Project (1,757 AD cases, 6,294 controls). The proposed mechanism involves local brain estrogen synthesis: aromatase is expressed in neurons and astrocytes, and locally produced estradiol modulates neuroinflammatory signaling via estrogen receptor beta. When aromatase activity is lower (CC genotype) AND IL-10 production is impaired (rs1800896 risk allele), the combined inflammatory environment in postmenopausal brain tissue may compound Alzheimer's risk beyond either variant alone. This interaction is not yet actionable as an independent clinical signal, but it illustrates the reach of aromatase regulation beyond bone.

rs700518 (also in CYP19A1, ~12 kb away) is the most studied bone-BMD variant in this gene and has a more robust evidence base for BMD effects in both sexes. Both variants modulate aromatase expression in bone but through distinct regulatory elements; their combined effect has not been formally characterized.

Polycystic ovary syndrome affects 5–15% of women of reproductive age and carries a substantially elevated risk of cardiovascular and thrombotic complications. A 2018 genome-wide meta-analysis by Day et al. in PLoS Genetics¹¹ Day et al. in PLoS Genetics
10,074 PCOS cases and 103,164 controls of European ancestry, fixed-effect inverse-variance-weighted meta-analysis identified rs10739076 near the PLGRKT gene as one of three newly discovered PCOS susceptibility loci — reaching genome-wide significance (P<5×10⁻⁸). PLGRKT encodes the plasminogen receptor with a C-terminal lysine, a transmembrane protein that is central to the fibrinolytic system and, as emerging data show, to metabolic regulation in adipose tissue.

The Mechanism

PLGRKT (Plg-RKT)²² PLGRKT (Plg-RKT)
plasminogen receptor with C-terminal lysine; gene ID 55848, chromosome 9, complement strand is a structurally unique transmembrane receptor that tethers plasminogen to the surface of cells by exposing a C-terminal lysine residue. Plasminogen bound to Plg-RKT is co-localized with the urokinase receptor (uPAR), allowing efficient conversion to plasmin³³ plasmin
a broad-spectrum serine protease that degrades fibrin clots and extracellular matrix. This cell-surface plasmin generation is the final step of fibrinolysis — the process that dissolves blood clots after they form.

The rs10739076 variant lies approximately 2 kb downstream of PLGRKT's last exon in an intergenic region that likely contains regulatory elements influencing PLGRKT expression. The locus also neighbors the relaxin/insulin-like family genes INSL4, INSL6, RLN1, and RLN2, which are endocrine hormones with roles in reproductive function. The C risk allele at rs10739076 is the population-major allele globally (~65%), meaning most people — and most women with PCOS — carry at least one C allele.

Beyond fibrinolysis, Samad et al. 2022⁴⁴ Samad et al. 2022
using adipose tissue from bariatric surgery patients and high-fat-diet mice lacking PLGRKT showed that PLGRKT deficiency leads to increased adipose inflammation, insulin resistance, hepatic steatosis, and impaired PPARγ signaling — linking this plasminogen receptor to the metabolic dysregulation characteristic of PCOS.

The Evidence

Women with PCOS already have a well-documented prothrombotic state independent of genotype. Mannerås-Holm et al. 2011 (74 PCOS women, 31 controls)⁵⁵ Mannerås-Holm et al. 2011 (74 PCOS women, 31 controls)
Journal of Clinical Endocrinology & Metabolism found significantly elevated PAI-1 activity (the primary inhibitor of fibrinolysis) and fibrinogen in PCOS, with PAI-1 predicted by high insulin and low SHBG (R²=0.526, P<0.001). Burchall et al. 2016 (107 PCOS/67 controls)⁶⁶ Burchall et al. 2016 (107 PCOS/67 controls)
Seminars in Thrombosis and Hemostasis confirmed "impaired fibrinolysis in PCOS" with PAI-1 elevated at 4.80 vs 3.66 U/mL (p<0.01) independent of age and BMI, plus elevated plasminogen levels — a pattern consistent with an overloaded fibrinolytic system that can't keep up with clot formation.

The rs10739076 C allele adds a genetic layer to this baseline prothrombotic risk. The 2024 Indian cohort study by Dadachanji et al. (497 PCOS cases, 233 controls)⁷⁷ Dadachanji et al. (497 PCOS cases, 233 controls)
European Journal of Obstetrics & Gynaecology found that rs10739076 was associated with reduced fasting glucose and protective effects on insulin resistance, gonadotropin, and lipid levels in PCOS women — suggesting the variant modifies metabolic severity within PCOS rather than simply conferring susceptibility. The 2025 multi-ancestry GWAS by Zhao et al. in Nature Genetics⁸⁸ 2025 multi-ancestry GWAS by Zhao et al. in Nature Genetics
12,419 Chinese + 13,773 European PCOS cases; 94 independent loci identified confirmed substantial cross-ancestry genetic architecture for PCOS, validating the PLGRKT-adjacent locus as a robust PCOS susceptibility signal.

Epidemiologically, the thrombotic consequences are clear: PCOS women have approximately a 2-fold elevated risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) versus controls, with the risk rising further with combined oral contraceptive use (RR 2.14, 95% CI 1.41–3.24).

Practical Actions

For women carrying the C risk allele — particularly CC homozygotes — the combination of PCOS biology and genetic predisposition at the fibrinolytic locus warrants specific attention to thrombotic risk factors. Marine omega-3 fatty acids (EPA/DHA) have consistent evidence for improving metabolic dysfunction in PCOS: reducing triglycerides, decreasing insulin resistance (negative association with HOMA-IR, β=−0.089), and reducing inflammatory markers. A 2024 review of clinical trials found n-3 PUFAs demonstrate "hypotriglyceridemic, cardioprotective and anti-inflammatory effects" in PCOS, making them a well-supported adjunct to standard care.

PAI-1 levels — the direct marker of fibrinolytic impairment — should be monitored in CC homozygotes with confirmed or suspected PCOS, as elevated PAI-1 combined with genetic susceptibility at the PLGRKT locus creates compounding prothrombotic risk. Oral contraceptive selection is particularly relevant: combined oral contraceptives (COCs) independently increase VTE risk ~2-fold in PCOS, so progestin-only options or non-hormonal methods may be preferable in women with additional thrombotic risk factors.

Interactions

rs2479106 and rs7852296 (DENND1A): These PCOS susceptibility loci at chromosome 9q33.3 affect androgen biosynthesis in theca cells. Women carrying risk alleles at both DENND1A and PLGRKT loci may have compounding PCOS severity — elevated androgens driving the hormonal phenotype alongside impaired fibrinolysis driving thrombotic risk. No compound effect study has directly examined this combination.

rs13405728 (LHCGR): The LH/hCG receptor PCOS locus. Elevated LH in PCOS independently elevates thrombotic risk through platelet activation; combination of LHCGR and PLGRKT locus risk genotypes represents a plausible but unstudied compound thrombotic risk pathway.

Every woman is born with her entire lifetime supply of eggs already formed. These primordial follicle oocytes sit in meiotic arrest, sometimes for decades, under constant threat from DNA damage accumulating over time — from metabolic byproducts, environmental toxins, radiation, and the simple passage of years. The protein that decides which of these oocytes survive and which are eliminated is TAp63α, an isoform of the p53 family member TP63¹¹ TAp63α, an isoform of the p53 family member TP63
TAp63α (Tumor Protein p63, alpha isoform) is expressed at exceptionally high levels in primordial follicle oocytes and acts as the transcriptional master regulator of genome integrity in this cell type. rs10804920 is an intronic variant within the TP63 gene on chromosome 3. In a landmark genome-wide association study, the T allele at this variant was associated with significantly later age at natural menopause — a signal that reflects better lifetime preservation of the ovarian follicle pool.

The Mechanism

TAp63α patrols primordial oocytes for unresolved DNA damage. In its inactive state it exists as a closed, dimeric structure. When checkpoint kinases detect double-strand DNA breaks — either from meiotic recombination errors or environmental genotoxic damage — CHK2 phosphorylates TAp63α first (priming), and then CK1 provides a second, decisive phosphorylation that opens the protein into its active tetrameric form²² CHK2 phosphorylates TAp63α first (priming), and then CK1 provides a second, decisive phosphorylation that opens the protein into its active tetrameric form
This sequential two-kinase activation model was established by structural biology studies at Goethe University Frankfurt. The activated TAp63α tetramer then functions as a transcription factor, driving expression of pro-apoptotic genes Puma and Noxa³³ Puma and Noxa
PUMA (p53 upregulated modulator of apoptosis) and NOXA are BCL-2 family proteins that release BAX/BAK to execute the mitochondrial apoptosis program. The result: the oocyte eliminates itself before its damaged DNA can be passed to an embryo.

The rs10804920 variant is intronic, meaning it does not alter the TAp63α protein sequence directly. Instead, it likely acts as a regulatory variant affecting TAp63α expression levels or isoform balance in primordial follicle oocytes — the tissue where TP63 expression is concentrated. The T allele (associated with later menopause) may reflect fine-tuned checkpoint activity that better distinguishes reparable from irreparable damage, preserving more healthy oocytes over time. The exact regulatory mechanism at this locus remains to be characterized.

The Evidence

The primary evidence comes from a 2021 genome-wide association study published in Nature by Ruth, Day, and colleagues⁴⁴ 2021 genome-wide association study published in Nature by Ruth, Day, and colleagues
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393-397, 2021, analysing age at natural menopause in approximately 200,000 women of European ancestry with replication in additional cohorts. rs10804920-T was identified as a genome-wide significant locus (p = 7×10⁻¹⁹) with a beta of 0.076 years per T allele — meaning each copy of the T allele is associated with approximately 1 month of later menopause timing. Women carrying TT (two protective T alleles) would be expected to experience menopause approximately 2 months later than CC homozygotes at this locus alone, reflecting cumulative effects across a lifetime of oocyte quality control.

The biological plausibility of TP63 as an ovarian aging determinant is exceptionally strong. Bolcun-Filas et al. demonstrated in Science (2014) that ablating the checkpoint kinase CHK2 completely reverses female infertility caused by either meiotic defects or ionizing radiation⁵⁵ Bolcun-Filas et al. demonstrated in Science (2014) that ablating the checkpoint kinase CHK2 completely reverses female infertility caused by either meiotic defects or ionizing radiation
Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science 343:533-536, proving that the CHK2→p63 axis is the dominant pathway eliminating damaged oocytes. Kerr et al. (Mol Cell, 2012) further showed that γ-irradiated female mice lacking Puma (the TAp63 downstream target) retain their fertility and produce healthy offspring at the same rate as unirradiated controls⁶⁶ Kerr et al. (Mol Cell, 2012) further showed that γ-irradiated female mice lacking Puma (the TAp63 downstream target) retain their fertility and produce healthy offspring at the same rate as unirradiated controls
DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol Cell 48:343-352, establishing TAp63→Puma/Noxa as the mechanistically proven link between DNA damage exposure and ovarian reserve depletion.

Practical Implications

Because TP63 checkpoint activity is central to how oocyte DNA damage translates into follicle loss, exposures that increase DNA damage burden in primordial oocytes are directly relevant to this locus: ionizing radiation (medical scans, occupational exposure), tobacco smoke, certain chemotherapy agents, and persistent organic pollutants are documented genotoxic stressors for the ovary. Reducing unnecessary exposure lowers the signal reaching the TP63 checkpoint, which translates to slower reserve depletion over the reproductive lifespan.

Two supplements have documented evidence for reducing oocyte DNA damage upstream of the checkpoint. CoQ10 (ubiquinol form) suppresses DNA damage and apoptosis in aged oocytes by restoring mitochondrial function and reducing reactive oxygen species⁷⁷ suppresses DNA damage and apoptosis in aged oocytes by restoring mitochondrial function and reducing reactive oxygen species
Zhang et al. 2019, Free Radical Biology and Medicine, and melatonin enhances DNA double-strand break repair (NHEJ pathway) in oocytes during prophase arrest, reducing the γ-H2AX damage signal and preserving spindle integrity⁸⁸ enhances DNA double-strand break repair (NHEJ pathway) in oocytes during prophase arrest, reducing the γ-H2AX damage signal and preserving spindle integrity
Leem et al. 2019, Journal of Pineal Research. Both act upstream of the TAp63 checkpoint — by reducing the quantity of DNA damage that triggers it, fewer oocytes reach the apoptotic threshold.

Interactions

CHK2 pathway variants (ATM, CHEK2): The CHK2→TAp63 axis that activates p63 is itself regulated by upstream DNA damage sensor kinases. Variants in ATM (rs1801516) or CHEK2 (rs17879961) that affect checkpoint kinase activity would modulate how efficiently DNA damage is transmitted to TAp63. Women carrying unfavorable genotypes at both a TP63 regulatory variant and an upstream kinase variant (ATM, CHK2) may have an amplified or attenuated response to genotoxic exposures compared to either variant alone — a compound action candidate warranting dedicated analysis when both loci are in the database.

rs116098458 (TP63 regulatory variant): Other intronic and regulatory variants within TP63 may influence TAp63α expression in primordial follicle oocytes differently from rs10804920. The combined effect of multiple TP63 regulatory variants on checkpoint stringency has not yet been characterised in the literature.

Two genes sit on chromosome 9q33-34, separated by roughly 10 kilobases of intergenic DNA: TRAF1, a signaling adapter that modulates NF-kB activation, and C5, the complement protein that bridges innate and adaptive immunity. The rs10818488 polymorphism lies exactly in this gap — a regulatory SNP¹¹ SNP
Single nucleotide polymorphism — a single-letter DNA difference that varies between people that is one of the most robust and well-replicated non-HLA risk loci for rheumatoid arthritis (RA) identified to date. The A allele, carried by approximately 42% of Europeans, confers measurably elevated RA risk and is associated with faster joint destruction in established disease.

The Mechanism

rs10818488 maps to the intergenic region approximately 10 kb from both the TRAF1 and C5 transcription start sites. It does not change any protein directly. Instead, it alters the local regulatory landscape: the A allele creates a binding site for EP300²² A allele creates a binding site for EP300
EP300 is a histone acetyltransferase that opens chromatin and activates transcription; binding at this locus appears to alter TRAF1 expression levels in immune cells, a histone acetyltransferase that remodels chromatin and activates transcription. Experimental evidence from monocytes confirms the functional direction: carriers of risk alleles at this locus express less TRAF1 protein³³ less TRAF1 protein
Paradoxically, reduced TRAF1 expression leads to more inflammation because TRAF1 normally sequesters LUBAC, the linear ubiquitin assembly complex; without sufficient TRAF1, LUBAC is released and drives stronger NF-kB activation upon stimulation and produce increased amounts of TNF and IL-6. TRAF1's role in NF-kB regulation is paradoxical: while it amplifies survival signaling through TNFR family members, it also suppresses excessive TLR/NLR responses by sequestering LUBAC. Lower TRAF1 expression tips this balance toward enhanced inflammatory cytokine output.

This creates a self-reinforcing loop in RA pathogenesis: reduced TRAF1 expression → amplified TNF production → further joint inflammation → progressive erosive disease. The A allele's association with radiographic damage progression reflects exactly this mechanism.

The Evidence

The TRAF1-C5 locus was first established as an RA risk locus by Plenge et al. in the New England Journal of Medicine⁴⁴ Plenge et al. in the New England Journal of Medicine
A landmark 2007 genome-wide association study with stepwise replication across Dutch, Swedish, and US cohorts (2007), with rs10818488 confirmed across 2,719 RA patients and 1,999 controls (OR 1.28, 95% CI 1.17–1.39, p = 1.40×10⁻⁸). The population-attributable risk — the fraction of RA cases attributable to this variant — was 6.1%, making it one of the most consequential non-HLA loci. A candidate gene study⁵⁵ candidate gene study
Using targeted genotyping of biologically plausible genes rather than genome-wide scanning replicated the finding across four independent sample sets: the A allele gave an OR of 1.26 overall, with AA homozygotes showing OR 2.06 (95% CI 1.42–2.98) compared with GG carriers.

A meta-analysis of 24 studies⁶⁶ meta-analysis of 24 studies
Pooling 22,682 RA cases and 23,493 controls confirmed the association in Europeans (OR 1.229, 95% CI 1.094–1.381, p=0.001) but not significantly in Asians, where the directional effect is reversed in some analyses — a genuine genetic heterogeneity reflecting different LD patterns at this locus across ancestries. An updated meta-analysis⁷⁷ updated meta-analysis
21 studies, 15,171 cases and 13,998 controls, with population-stratified analysis found the G allele is paradoxically protective in Europeans but a weak risk allele in Asians, consistent with the A allele's European-ancestry risk direction.

Beyond susceptibility, the A allele is associated with disease severity: carriers show greater radiographic joint damage progression over time (p=0.008). Association with higher disease activity scores has been replicated in Middle Eastern populations. The variant also extends to systemic lupus erythematosus, with an OR of 1.21 (95% CI 1.12–1.31, p=5.0×10⁻⁶) in Europeans in a separate meta-analysis⁸⁸ a separate meta-analysis.

Practical Actions

For AA homozygotes carrying two copies of the risk allele, the priority is early recognition of RA symptoms and baseline autoantibody testing — anti-CCP (ACPA) and rheumatoid factor — since the A allele's risk is predominantly expressed in seropositive, erosive RA. Joint stiffness lasting over 30 minutes in the morning, symmetric swelling of small hand joints, and unexplained fatigue are the key early warning signs. Because this locus also influences response to anti-TNF biologics (rs3761847, a nearby proxy SNP at the same locus, predicts anti-TNF outcomes), genotype information from this region may eventually guide biologic selection.

For the heterozygous AG genotype, the modestly elevated risk warrants awareness rather than aggressive clinical action, unless compounded by HLA-DRB1 shared epitope alleles or PTPN22 R620W carriage.

Interactions

rs10818488 and rs3761847 are the two most studied SNPs at the TRAF1-C5 locus, located approximately 10 kb apart in the same intergenic haplotype block. In most populations they are in high linkage disequilibrium and tag the same risk haplotype. The nearby rs3761847 G allele has been associated with poor response to anti-TNF therapy in RA, while rs10818488 A allele captures the overall susceptibility signal. Carrying risk alleles at both SNPs likely identifies the highest-risk individuals at this locus.

PTPN22 rs2476601 (R620W) is the strongest non-HLA non-TRAF1 RA susceptibility variant; combined carriage of PTPN22 A allele and TRAF1-C5 A allele substantially elevates RA risk beyond either alone through independent immune signaling pathways (T-cell signaling threshold versus NF-kB regulation). TNFAIP3 rs13207033, a protective NF-kB regulatory variant at the 6q23 locus, may partially offset TRAF1-C5 risk through independent A20-mediated NF-kB suppression.

Vitamin D from sunlight or supplements is biologically inert until the liver converts it into 25-hydroxyvitamin D (25(OH)D)¹¹ 25-hydroxyvitamin D (25(OH)D)
Also called calcidiol — the main circulating form of vitamin D, and the standard measure of your vitamin D status on a blood test. From here, the kidneys make the fully active hormone calcitriol. This first hydroxylation step is performed primarily by a cytochrome P450 enzyme called CYP2R1, encoded on chromosome 11p15.2. Without this enzyme working efficiently, neither sun exposure nor dietary vitamin D can adequately raise circulating 25(OH)D levels.

The rs10832310 variant is an intronic tag SNP located in the neighboring PDE3B gene but in high linkage disequilibrium with regulatory variants at the CYP2R1 locus. The G allele marks a haplotype associated with reduced CYP2R1 expression or activity, resulting in less efficient 25-hydroxylation of vitamin D3.

The Mechanism

CYP2R1 is a microsomal cytochrome P450 enzyme expressed primarily in the liver, where it catalyzes the addition of a hydroxyl group to carbon-25 of vitamin D3 (cholecalciferol), converting it to 25(OH)D3. Cheng et al. 2004²² Cheng et al. 2004
Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. PNAS, 2004 provided definitive evidence for this role by identifying a patient with an inherited homozygous L99P mutation in CYP2R1 who had very low circulating 25(OH)D despite normal sun exposure and dietary intake. The mutation abolished enzyme activity entirely.

The rs10832310 G allele does not alter the CYP2R1 protein sequence directly — it tags a haplotype block that likely includes regulatory variants affecting CYP2R1 transcription. Colocalization analysis in the Kämpe et al. 2019 GWAS³³ Kämpe et al. 2019 GWAS
Kämpe A et al. Genetic variation in GC and CYP2R1 affects 25-hydroxyvitamin D concentration and skeletal parameters: A genome-wide association study in 24-month-old Finnish children. PLoS Genetics, 2019 found a 97.3% posterior probability of a shared causal variant between the GWAS signal and CYP2R1 expression in thyroid tissue, strongly implicating altered gene expression as the mechanism.

The Evidence

The primary GWAS identifying rs10832310 was conducted in 761 healthy term-born Finnish children at 24 months of age, who participated in a randomized clinical trial comparing 10 μg versus 30 μg daily vitamin D3 supplementation from age 2 weeks. The GWAS signal reached p = 4.24 × 10⁻¹¹, genome-wide significance. The G allele was associated with a decrease of approximately 7.5 units in serum 25(OH)D — a clinically meaningful reduction for a pediatric population. Critically, the effect size was consistent regardless of whether children received standard-dose or high-dose vitamin D3, indicating that this locus reduces baseline conversion efficiency rather than modulating supplementation response directly.

Haplotypes associating with low 25(OH)D at this locus also showed strong negative associations with pQCT (peripheral quantitative computed tomography) bone parameters at the distal tibia, consistent with vertical pleiotropy⁴⁴ vertical pleiotropy
An effect where one variant influences multiple downstream traits through a single causal pathway — here, lower 25(OH)D leads to reduced calcium absorption and impaired bone mineralization mediated by vitamin D status.

The broader CYP2R1 locus has been replicated in multiple independent GWAS. The Wang et al. 2010 Lancet GWAS⁵⁵ Wang et al. 2010 Lancet GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010 of 33,996 Europeans confirmed the chromosome 11 CYP2R1 region as one of three genome-wide significant loci for 25(OH)D, alongside DHCR7 (chromosome 11q) and GC (chromosome 4). The MrOS Sweden cohort⁶⁶ MrOS Sweden cohort
Björk A et al. Haplotypes in the CYP2R1 gene are associated with levels of 25(OH)D and bone mineral density, but not with other markers of bone metabolism. PLoS One, 2019 found 4.6–18.5% differences in mean 25(OH)D between CYP2R1 genotypes in a large adult cohort, with corresponding effects on femoral neck bone mineral density.

Beyond skeletal health, the CYP2R1 locus has been linked to type 1 diabetes risk⁷⁷ type 1 diabetes risk
Ramos-Lopez E et al. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev, 2007, multiple sclerosis susceptibility, and immune function — likely mediated through the immunomodulatory effects of calcitriol on regulatory T cells and antigen-presenting cells.

Practical Implications

The G allele at rs10832310 reduces the liver's ability to convert vitamin D3 into its circulating form, 25(OH)D. This means that sun exposure and dietary vitamin D are converted less efficiently. Supplementing with vitamin D3 (cholecalciferol) bypasses none of this step — it must still be hydroxylated by CYP2R1 — so GG carriers may need higher doses than standard recommendations to achieve the same circulating 25(OH)D levels. Monitoring via blood testing becomes more important to confirm that supplementation is achieving adequate levels rather than assuming a standard dose is sufficient.

The G allele is relatively common (approximately 37% globally, 43% in Europeans), making this a frequently relevant consideration. The effect is additive, so GG homozygotes experience roughly double the impact of CG heterozygotes.

Interactions

The CYP2R1 locus interacts with three other major vitamin D pathway variants. DHCR7 (rs12785878) controls how much substrate (7-dehydrocholesterol) reaches the skin synthesis pathway. GC/DBP (rs2282679) determines how efficiently 25(OH)D is transported in the blood. VDR (rs2228570, rs1544410) determines receptor sensitivity to active calcitriol. Wang et al. 2010 found that individuals in the highest-risk quartile across all three confirmed loci had 2.47 times the odds of vitamin D insufficiency compared to the lowest-risk quartile. Users carrying G alleles at both rs10832310 and other vitamin D pathway variants face compounding impairments across synthesis, transport, and receptor sensitivity.

When your HDL particles finish their journey through the bloodstream collecting excess cholesterol from tissues, they need somewhere to deliver it. That final destination is the liver, and the molecule that accepts the delivery is SR-BI¹¹ SR-BI
Scavenger Receptor class B type I — a cell-surface receptor that extracts cholesterol esters directly from HDL into hepatocytes, the critical last step of reverse cholesterol transport. The SCARB1 gene encodes SR-BI, and rs10846744 — an intronic variant — influences how well this receptor functions. Carriers of the C allele show measurably higher rates of subclinical atherosclerosis and coronary heart disease, even in the presence of normal or elevated HDL cholesterol levels.

The Mechanism

rs10846744 lies within an intron of SCARB1 on chromosome 12 (GRCh38: 12:124,827,879). As a non-coding variant, it does not change the SR-BI amino acid sequence, but it likely affects gene expression, mRNA splicing efficiency, or protein levels — collectively altering the rate at which HDL cholesterol can be cleared from circulation into the liver. When SR-BI function is compromised, HDL particles accumulate in the bloodstream. This creates the HDL paradox²² HDL paradox
Normally, higher HDL is protective. But if HDL is high because the receptor that removes it isn't working well, the cholesterol isn't actually being delivered to the liver for excretion — it's stuck in transit: an elevated HDL reading accompanied by impaired reverse cholesterol transport and, paradoxically, increased cardiovascular risk.

The Evidence

The strongest evidence comes from a MESA cohort analysis³³ MESA cohort analysis
Manichaikul et al. Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. ATVB, 2012 of 7,936 participants from four ethnic groups. The rs10846744 variant showed strong association with carotid intima-media thickness (cIMT) across all ethnicities (P=1.04×10⁻⁴), a validated marker of early atherosclerosis. In males specifically, the variant was significantly associated with incident cardiovascular disease events (P=0.01), with replication support in the Myocardial Infarction Genetics Consortium.

A subsequent multi-cohort study⁴⁴ multi-cohort study
Manichaikul et al. Lp-PLA2, SCARB1 rs10846744 variant, and cardiovascular disease. PLoS One, 2018 using CARDIoGRAMplusC4D data (hundreds of thousands of participants) confirmed that the C allele associates with coronary artery disease (OR 1.05, 95% CI 1.02–1.07, P=1.4×10⁻⁴). The same study found associations with Lp-PLA2 activity, LDL particle number, and DHA levels in MESA participants.

A Chinese Han cohort study⁵⁵ Chinese Han cohort study
Zeng et al. Influence of SCARB1 gene SNPs on serum lipid levels and susceptibility to coronary heart disease and cerebral infarction in a Chinese population. Gene, 2017 of 909 participants found the C allele significantly elevated CHD risk (OR 1.416, 95% CI 1.128–1.778, P=0.006). Notably, CC and CG carriers had higher HDL-cholesterol than GG carriers — illustrating the HDL paradox characteristic of SR-BI dysfunction.

Practical Actions

For C allele carriers, the impaired SR-BI function means the focus should shift from simply raising HDL cholesterol to optimizing HDL functionality and facilitating cholesterol clearance through alternative pathways. Omega-3 fatty acids (EPA and DHA) support HDL particle quality and enhance reverse cholesterol transport efficiency. Monitoring HDL function — not just HDL-C level — and tracking inflammatory markers such as Lp-PLA2 gives a more accurate cardiovascular risk picture than a standard lipid panel alone.

Interactions

rs10846744 is in the same gene as rs4238001 (an exonic SCARB1 variant), rs2278986 (another SCARB1 intronic SNP), and rs5888 (a synonymous coding variant). Combined analysis of multiple SCARB1 variants may capture more variance in SR-BI activity than any single SNP alone. SCARB1 also interacts with the APOE pathway (rs429358, rs7412): both genes govern how efficiently cholesterol is cleared from the bloodstream, so carriers of risk alleles in both genes may face compounded dysfunction in reverse cholesterol transport.

The QT interval¹¹ QT interval
the time between the start of ventricular depolarization and the end of repolarization, measured on an electrocardiogram is one of medicine's most important cardiac biomarkers. A prolonged QTc interval predisposes to torsades de pointes²² torsades de pointes
a dangerous polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death. Genetics account for roughly 30% of QTc variation in the population — and the NOS1AP gene harbors one of the strongest common genetic contributors ever discovered.

NOS1AP (also called CAPON — Carboxy-terminal PDZ ligand of Neuronal nitric Oxide synthase) encodes an adaptor protein that physically binds to neuronal nitric oxide synthase (nNOS). Though originally studied in the brain, nNOS is expressed in cardiac myocytes where it plays a key role in modulating calcium handling and action potential duration.

The Mechanism

nNOS in cardiomyocytes inhibits the L-type calcium channel³³ L-type calcium channel
the main inward calcium current that drives and prolongs cardiac contraction and activates the delayed rectifier potassium current. Together, these effects accelerate ventricular repolarization — shortening the action potential and therefore the QT interval. NOS1AP/CAPON interacts with nNOS and modulates the efficiency of this signaling cascade.

rs10918594 is a C>G variant located upstream of NOS1AP, approximately 55 kb from a second functional SNP in the same gene (rs10494366, r²=0.63, D′=0.89). Neither SNP is a coding variant — they sit in regulatory or non-coding sequence and have no known functional effect on the protein itself. Instead, they appear to tag a causal regulatory variant that alters NOS1AP expression in cardiac tissue. Direct evidence supports this interpretation: analysis of NOS1AP RNA levels in human right ventricular tissue⁴⁴ analysis of NOS1AP RNA levels in human right ventricular tissue
cardiac samples from 17 patients undergoing pacemaker lead extraction found that CC homozygotes (major allele) had lower NOS1AP expression than GG minor homozygotes. Lower NOS1AP expression correlates with shorter QTc — meaning the G allele raises NOS1AP/CAPON expression, which amplifies nNOS signaling and paradoxically reduces nNOS's ability to shorten the action potential. The net effect is prolonged repolarization.

The Evidence

The original discovery came from the landmark Rotterdam Study⁵⁵ Rotterdam Study
a prospective population-based cohort of 3,761 individuals aged ≥55 years in the Netherlands. The rs10918594 G allele (31% frequency in this European cohort) was associated with a 3.6-ms increase in QTc per additional allele copy (95% CI 2.7–4.4; P=6.9×10⁻¹⁷) — a highly significant genome-wide association replicated across dozens of subsequent studies. GG homozygotes averaged 7.2 ms longer QTc than CC homozygotes.

Replication in the Diabetes Heart Study⁶⁶ Diabetes Heart Study
European-American families with and without type 2 diabetes confirmed and extended the finding. Minor homozygotes had QT intervals 12.5 ms longer than major homozygotes overall (P=1.5×10⁻⁶). Critically, the effect was stronger among diabetic individuals (13.9-ms difference), suggesting that diabetic cardiomyopathy creates a permissive background in which NOS1AP-dependent calcium dysregulation is amplified.

Beyond QTc prolongation, NOS1AP variation is associated with sudden cardiac death (SCD) risk⁷⁷ NOS1AP variation is associated with sudden cardiac death (SCD) risk
in 233 SCD cases over 11.9 years of follow-up in the Rotterdam Study — and this SCD association appears to be at least partially independent of the effect on QT duration, suggesting NOS1AP influences arrhythmia susceptibility through mechanisms beyond simple QT prolongation.

NOS1AP has also emerged as a genetic modifier of congenital Long QT syndrome (LQTS)⁸⁸ genetic modifier of congenital Long QT syndrome (LQTS)
inherited channelopathies caused by loss-of-function mutations in KCNQ1, KCNH2, and SCN5A. Among LQTS patients, G allele carriers had higher rates of life-threatening cardiac events (24.8% vs 17.8%), and the variant independently predicted arrhythmia risk beyond QTc alone — meaning NOS1AP genotyping adds prognostic information on top of standard clinical assessment in these patients.

Drug-induced QT prolongation⁹⁹ Drug-induced QT prolongation
a major cause of drug withdrawal and black-box warnings across multiple drug classes is also modified by NOS1AP variants. The G allele was associated with increased risk of amiodarone-induced ventricular arrhythmia. The Rotterdam Study specifically showed that G allele carriers had a significantly potentiated QTc-prolonging response to verapamil (a calcium channel blocker) — consistent with the mechanistic role of NOS1AP in L-type calcium channel regulation.

A systematic meta-analysis published in 2019¹⁰¹⁰ systematic meta-analysis published in 2019
pooling data across multiple cohorts confirmed that the NOS1AP QTc association is particularly strong in women and in patients with diabetes mellitus, and that the sudden death association is significant in Caucasian populations.

Practical Actions

For carriers of one or two G alleles, the primary concern is QTc prolongation. A QTc above 450 ms in men or 460 ms in women is considered borderline prolonged; above 500 ms substantially elevates arrhythmia risk. NOS1AP's 3.6-ms-per-allele effect is modest in isolation — GG homozygotes average about 7 ms longer QTc — but the clinical stakes rise when other QT-prolonging factors stack on top.

Key risks to manage: certain medications (including many antiarrhythmics, antibiotics, antipsychotics, and antihistamines) prolong the QT interval independently, and G allele carriers face an amplified combined effect. Electrolyte disturbances — particularly hypokalemia and hypomagnesemia — further extend the QT interval and lower the threshold for torsades de pointes. Diabetics with G alleles face a compounded risk because both diabetic autonomic neuropathy and NOS1AP variants independently prolong QTc.

Interactions

The two principal NOS1AP SNPs — rs10918594 and rs10494366 — are in moderate linkage disequilibrium (r²=0.63) and are typically co-inherited. Their combined effects have not been formally quantified in a compound-genotype analysis, but given their shared locus and similar effect sizes, they likely tag the same functional regulatory variant rather than act through independent mechanisms.

Interaction with rs12143842 (and its proxy rs16847549), a neighboring NOS1AP variant, was the strongest SCD signal in the Rotterdam Study follow-up analysis. In the congenital LQTS context, NOS1AP G allele carriers with KCNQ1 variants also showed elevated risk — suggesting the NOS1AP-nNOS pathway compounds with the primary channelopathy.

Every protein in your blood has a molecular expiration date stamped on its surface as a sugar code. Von Willebrand factor (VWF)¹¹ Von Willebrand factor (VWF)
A large multimeric glycoprotein that anchors platelets to damaged vessel walls and carries Factor VIII through the circulation; plasma level is a major determinant of clotting tendency and Factor VIII (FVIII)²² Factor VIII (FVIII)
The cofactor in the intrinsic coagulation pathway; the two molecules circulate as a non-covalent complex and their plasma levels are tightly correlated both carry a coating of sialic acid residues on their glycan chains. When these sialic acids are intact, the proteins circulate freely. When they are absent or reduced, galactose residues on the protein surface become exposed and the liver's asialoglycoprotein receptors (ASGPR) recognize them as disposal targets — pulling them out of circulation. The ST3GAL4 enzyme determines how thoroughly this protective sialic acid coat is applied. Variants in its first intron, including rs11220465, tune this activity up or down in ways that directly shift the steady-state plasma levels of VWF and FVIII.

The Mechanism

ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4)³³ ST3GAL4 (ST3 beta-galactoside alpha-2,3-sialyltransferase 4)
One of the six ST3GAL family enzymes; acts in the Golgi apparatus to transfer sialic acid onto galactose residues at the termini of N- and O-linked glycan chains is expressed in endothelial cells (where VWF is synthesized and secreted) and hepatocytes. rs11220465 is an intronic variant located in the first intron of the ST3GAL4 gene at chr11:126387884 (GRCh38). It does not alter the enzyme's amino acid sequence. Instead, it sits in a regulatory region that likely contains transcription factor binding sites — bioinformatic analysis of the region identifies multiple regulatory motifs whose affinity changes with the A allele. The downstream consequence is a modest shift in ST3GAL4 activity that alters how completely VWF and FVIII are sialylated before secretion.

The causal mouse model is compelling: Ellies et al. 2002⁴⁴ Ellies et al. 2002
Knockout mice lacking ST3Gal-IV have plasma VWF levels approximately 50% of normal; intravenous asialofetuin (which competes for ASGPR binding sites) restores VWF half-life, directly demonstrating that ASGPR-mediated clearance of under-sialylated VWF is the mechanism. In humans, the A allele at rs11220465 appears to reduce effective sialylation rather than eliminate it, producing a quantitatively milder but directionally consistent shift toward faster VWF/FVIII clearance and lower steady-state levels. This is the opposite direction from the rarer rs35257264 T allele (which increases sialylation and raises VWF/FVIII) — an important contrast since both variants act at the same locus via the same enzyme.

The Evidence

The definitive human genetic study is Song et al. 2016⁵⁵ Song et al. 2016
Analysis of 12,117 participants from the multi-ethnic Atherosclerosis Risk in Communities (ARIC) cohort; associations tested for 14 ST3GAL4 SNPs against VWF antigen and FVIII activity; adjustment for age, sex, BMI, hypertension, diabetes, ever-smoking status, and ABO blood group. Among three ST3GAL4 intronic SNPs associated with both VWF and FVIII, rs11220465 showed a VWF difference of approximately 10% between GG homozygotes (mean ~99% of normal) and AA homozygotes (mean ~109%), and was significantly associated with FVIII activity after full covariate adjustment (p=0.0002).

The VWF and FVIII association with VTE risk is well-documented in epidemiological data. Rietveld et al. 2019⁶⁶ Rietveld et al. 2019
Case-control study; 2,377 venous thrombosis cases and 2,940 controls; tested eight coagulation factors; VWF and FVIII showed by far the strongest associations with VTE among all factors tested found that VWF above the 99th percentile carries an OR of 24.0 (95% CI 15.3–37.3) for VTE, and FVIII an OR of 23.0 — the strongest associations among all coagulation factors studied. Edvardsen et al. 2021⁷⁷ Edvardsen et al. 2021
Prospective cohort with incident VTE events; dose-response analysis across quartiles; strongest association seen for unprovoked VTE and DVT found a dose-dependent VTE risk across VWF quartiles: highest vs. lowest quartile OR 1.45 overall (95% CI 1.03–2.03), rising to OR 2.74 (95% CI 1.66–4.54) for unprovoked VTE.

For rs11220465 specifically, the effect on VWF/FVIII is modest — roughly 5–10% per A allele at the population mean level — placing it solidly in the moderate rather than strong evidence tier for direct thrombosis risk prediction. The variant is nonetheless clinically informative as part of a cumulative VWF/FVIII risk picture, particularly when VWF or FVIII levels are elevated on direct measurement.

Practical Actions

Because the A allele's effect operates through quantitative elevation of VWF and FVIII, the most actionable step is to measure these proteins directly to determine whether your levels fall in a clinically elevated range. The ~10% shift seen between GG and AA homozygotes can combine with other factors — ABO blood type (non-O individuals already have ~25% higher VWF), oral contraceptive use, obesity, and age — to push total VWF into the range where VTE risk becomes clinically significant.

Co-inherited thrombophilic variants (Factor V Leiden rs6025, prothrombin G20210A rs1799963) act through mechanistically independent pathways and their effects are additive with VWF/FVIII elevation. If you also carry rs35257264 T allele (the rarer, sialylation-upregulating ST3GAL4 variant), both operate at the same locus but may show some non-additivity depending on haplotype structure.

Interactions

rs11220465 clusters within ~4 kb of rs2186717 and rs7928391 in the first intron of ST3GAL4 (Song et al. 2016). These three variants were identified as distinct signals — rs11220465 was not in perfect linkage disequilibrium with the other two, suggesting it may tag a partially independent regulatory element. The nearby rs35257264 (chr11:126426921) is a rarer variant (~2% MAF in Europeans) at a different intronic position with stronger per-allele effects and direct replication in VTE GWAS meta-analyses.

ABO blood type is the dominant genetic modifier of VWF levels; non-O blood groups inhibit VWF clearance through a separate mechanism and raise VWF approximately 25% above blood group O levels. The ST3GAL4 rs11220465 effect was confirmed independent of ABO in the Song et al. analysis, meaning both effects contribute additively to total VWF level.

UCP3 (uncoupling protein 3)¹¹ UCP3 (uncoupling protein 3)
A mitochondrial inner membrane protein expressed predominantly in skeletal muscle and, to a lesser extent, brown adipose tissue has long been debated as a thermogenic protein. The current consensus, however, points to a different primary role: protecting skeletal muscle mitochondria from the toxic accumulation of excess fatty acids. rs11235972 is an intronic variant in UCP3 on chromosome 11 that sits in strong linkage disequilibrium with the functional promoter variant rs1800849 — making it a reliable tag SNP for the functional haplotype. Studies have linked the A allele of rs11235972 to lower hand grip strength and higher mortality in aging cohorts, suggesting that reduced UCP3 function impairs the muscle's ability to handle fat loads as we age.

The Mechanism

UCP3 operates at the junction of fat utilization and mitochondrial health. When skeletal muscle cells receive more fatty acids than their oxidative machinery can immediately process, excess fatty acid anions and lipid peroxides build up inside the mitochondrial matrix — a condition called lipotoxicity²² lipotoxicity
Accumulation of lipid intermediates that damage mitochondrial membranes, impair electron transport, and generate reactive oxygen species. UCP3 exports these excess fatty acid anions out of the matrix, protecting the mitochondrial membranes and electron transport chain. It also appears to limit reactive oxygen species (ROS)³³ reactive oxygen species (ROS)
Unstable oxygen-containing molecules produced as a byproduct of energy metabolism that damage proteins, lipids, and DNA when they accumulate production during fatty acid oxidation.

rs11235972 is located within intron 5 of UCP3 and does not alter the protein directly. Its biological effect likely operates through the haplotype it tags: the functional promoter SNP rs1800849 (in D'=0.97 LD) controls UCP3 transcription, with the T allele of rs1800849 (tagging the common G allele of rs11235972) driving higher UCP3 expression in skeletal muscle. Individuals carrying the A allele of rs11235972 are thus more likely to express lower UCP3 protein levels, impairing the muscle's lipid-handling capacity.

The Evidence

The most direct evidence comes from Dato et al. 2012⁴⁴ Dato et al. 2012
Two Danish cohorts: middle-aged N=708 and oldest-old N=908, which found that the A allele at rs11235972 was associated with lower hand grip strength at both the single-SNP and haplotype level — consistently across both cohort ages. Beyond grip strength, A allele carriers showed higher 10-year mortality rates, suggesting that impaired UCP3 function in skeletal muscle affects functional reserve during aging. Hand grip strength is a robust biomarker of overall muscle quality and a predictor of all-cause mortality in older adults.

A complementary line of evidence comes from the UCP3 promoter variant rs1800849 (in near-perfect LD with rs11235972): the Montesanto et al. 2011⁵⁵ Montesanto et al. 2011
Large aged Italian cohort, ages 65-105 cohort found that the T allele of rs1800849 (corresponding to higher UCP3 expression) was associated with superior grip strength, and the authors concluded that efficient uncoupling activity has a protective effect on aging muscle by slowing mitochondrial decay.

At the mechanistic level, Nabben et al. 2011⁶⁶ Nabben et al. 2011
UCP3 knockout mice on 8-week and 26-week high-fat diets demonstrated that UCP3-null mice develop elevated mitochondrial ROS production within 8 weeks and measurably reduced mitochondrial function after 26 weeks of high-fat diet — establishing a causal role for UCP3 in protecting against lipid-induced mitochondrial dysfunction. Schrauwen et al. 2006⁷⁷ Schrauwen et al. 2006
Comprehensive mechanistic review noted that low UCP3 expression is a consistent feature of insulin-resistant and type 2 diabetic muscle, linking impaired fatty acid handling to downstream metabolic disease.

A Brazilian pediatric case-control study (Fortes et al. 2023⁸⁸ Fortes et al. 2023
225 children, 123 obese) found rs11235972 in a two-SNP haplotype block (with rs1800849) that showed linkage disequilibrium with adverse lipid profiles. While the effect size for rs11235972 individually was not isolated, the haplotype data supports its role in lipid metabolism across the lifespan.

Practical Actions

For A allele carriers — particularly those with the AA genotype — the impaired UCP3 activity means skeletal muscle mitochondria are less efficient at exporting excess fatty acids and controlling ROS during high-fat conditions. The key strategies involve supporting mitochondrial function directly, managing the fatty acid load that reaches muscle cells, and monitoring for markers of mitochondrial oxidative stress.

High-fat dietary patterns over the long term impose the greatest burden on UCP3-dependent protection. Shifting toward fat sources that are more readily oxidized (e.g., medium-chain fats and omega-3 polyunsaturates) rather than long-chain saturated fats reduces the lipotoxic load. Ubiquinol (the reduced form of coenzyme Q10) supports the electron transport chain efficiency and reduces upstream ROS production — particularly relevant when UCP3's ROS-limiting function is impaired.

Resistance and endurance training both upregulate UCP3 expression in skeletal muscle, providing a compensatory mechanism. This effect is especially important for A allele carriers: training-induced UCP3 upregulation may partially compensate for genetically lower basal expression.

Interactions

rs11235972 sits in strong LD (D'=0.97) with rs1800849, the promoter variant that directly controls UCP3 transcription. Most published studies on UCP3 functional effects have examined rs1800849; rs11235972 largely captures the same haplotype signal. Compound heterozygosity with rs1800849 (when the two are not in perfect LD in a specific individual) may have independent effects.

UCP3 operates in the same mitochondrial pathway as UCP1 (brown fat thermogenesis) and UCP2 (broad tissue expression). Variants in UCP2 (notably rs659366) that reduce mitochondrial uncoupling could theoretically compound with UCP3 A allele effects on overall mitochondrial ROS protection in skeletal muscle. No published compound interaction studies exist for rs11235972 × UCP2 variants, but the mechanistic rationale is strong given their shared function.

PGC-1α (PPARGC1A, rs8192678) is the master regulator of mitochondrial biogenesis and upregulates UCP3 expression in response to exercise; individuals with combined low PGC-1α function and low UCP3 expression may have compounded impairment in exercise-induced mitochondrial adaptation.